IL-21 and IL-12 inhibit differentiation of Treg and T H17 cells and enhance cytotoxicity of peripheral blood mononuclear cells in patients with cervical cancer

International Journal of Gynecological Cancer

Volumn 21, Issue 9, 2011, Pages 1672-1678

  Tian, Yongju ^a   Yuan, Cunzhong ^a   Ma, Daoxin ^a   Zhang, Yan ^a   Liu, Yi ^b   Zhang, Wenjing ^a   Hou, Fei ^a   Cui, Baoxia ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Cervical cancer; Cytokines; Cytotoxicity; Regulatory T cells; T helper 17 cells

Indexed keywords

CD4 ANTIGEN; CHOLECYSTOKININ OCTAPEPTIDE; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 21; LACTATE DEHYDROGENASE; TRANSCRIPTION FACTOR FOXP3; INTERLEUKIN DERIVATIVE;

ADULT; APOPTOSIS; ARTICLE; CANCER PATIENT; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME RELEASE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH17 CELL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; BLOOD; CASE CONTROL STUDY; CELL DIFFERENTIATION; DRUG EFFECT; IMMUNOLOGY; MONONUCLEAR CELL; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

ADULT; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; INTERLEUKIN-12; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; UTERINE CERVICAL NEOPLASMS;

EID: 84863229119     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182358955     Document Type: Article

References (24)

1. Bais AG, Beckmann I, Ewing PC, et al. Cytokine release in HR-HPV (+) women without and with cervical dysplasia (CIN II and CIN III) or carcinoma, compared with HR-HPV (j) controls. Mediators Inflamm. 2007;2007:24147.
2. Watanabe M, Kono K, Kawaguchi Y, et al. Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma. Br J Cancer. 2010;102:520-529.
3. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531-562.
4. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103:1755-1762. (Pubitemid 38268969)
5. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756-2761. (Pubitemid 34921025)
6. H17 and Treg skewing. Clin Cancer Res. 2008;14:3254-3261.
7. Zhang JP, Yan J, Xu J, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 2009;50:980-989.
8. Skak K, Kragh M, Hausman D, et al. Interleukin 21: combination strategies for cancer therapy. Nat Rev Drug Discov. 2008;7:231-240.
9. Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007;448:480-483. (Pubitemid 47123514)
10. Del Vecchio M, Bajetta E, Canova S, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res. 2007;13:4677-4685. (Pubitemid 47294773)
11. Cao X, Leonard K, Collins LI, et al. Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. Cancer Res. 2009;69:8700-8709.
12. Li J, Li L, Shang XZ, et al. Negative regulation of IL-17 production by OX40/OX40L interaction. Cell Immunol. 2008;253:31-37.
13. Wolf AM, Rumpold H, Reimer D, et al. High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer. Gynecol Oncol. 2010;118:244-250.
14. Hashmi MH, Van Veldhuizen PJ. Interleukin-21: updated review of phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma. Expert Opin Biol Ther. 2010;10:807-817.
15. Tartour E, Fossiez F, Joyeux I, et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res. 1999;59:3698-3704. (Pubitemid 29381875)
16. H17/Treg in patients with uterine cervical cancer. Clin Chim Acta. 2011;412:894-900.
17. + cytotoxic T lymphocytes. Blood. 2008;111:229-235.
18. Skak K, Frederiksen KS, Lundsgaard D. Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. J Immunol. 2008;123:575-583. (Pubitemid 351280971)
19. Ostiguy V, Allard EL, Marquis M, et al. IL21 promotes T lymphocyte survival by activating the phosphatidylinositol-3 kinase signaling cascade. J Leukoc Biol. 2007;82:645-656. (Pubitemid 47367157)
20. Rovedatti L, Kudo T, Biancheri P, et al. Differential regulation of interleukin 17 and interferon γ production in inflammatory bowel disease. Gut. 2009;58:1629-1636.
21. Yin X, Yan X, Yang Q, et al. Antitumor mechanism of recombinant murine interleukin-12 vaccine. Cancer Biother Radiopharm. 2010;25:263-268.
22. Wadler S, Levy D, Frederickson HL, et al. A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. Gynecol Oncol. 2004;92:957-964. (Pubitemid 38251402)
23. Peluso I, Fantini MC, Fina D, et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol. 2007;178:732-739. (Pubitemid 46095145)
24. + regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J Immunol. 2006;176:1750-1758.